ConductScience.org, home

Paper23908669

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea.

Moon BS and 2 others. Korean J Pediatr, 2013. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea. Papers, record 23908669. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23908669

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea.
PubMed
Journal
Korean J Pediatr
PubMed
Year
2013
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
0.09
iCite
Revised in PubMed
2021-10-21
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Moon BSByung Suk
2Choi JSJun Seok
3You CWChur Woo

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115569163A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.Haemophilia2004https://conductscience.org/library/papers/15569163PubMed
217687129Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.N Engl J Med2007https://conductscience.org/library/papers/17687129PubMed
319143924Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.J Thromb Haemost2009https://conductscience.org/library/papers/19143924PubMed
4780375The history of haemophilia.J Clin Pathol1976https://conductscience.org/library/papers/780375PubMed
5849938Hemophilic arthropathy. Current concepts of pathogenesis and management.J Bone Joint Surg Am1977https://conductscience.org/library/papers/849938PubMed
69873763When should prophylactic treatment in patients with haemophilia A and B start?--The German experience.Haemophilia1998https://conductscience.org/library/papers/9873763PubMed
75854304Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B.Acta Orthop Scand Suppl1965https://conductscience.org/library/papers/5854304PubMed
816011583Thrombin generation and phenotypic correlation in haemophilia A.Haemophilia2005https://conductscience.org/library/papers/16011583PubMed
911136389What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?Haemophilia2001https://conductscience.org/library/papers/11136389PubMed
1015660988Effects of haemophilic arthropathy on health-related quality of life and socio-economic parameters.Haemophilia2005https://conductscience.org/library/papers/15660988PubMed
1116128885Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed.Haemophilia2005https://conductscience.org/library/papers/16128885PubMed
129873783The destructive capabilities of the synovium in the haemophilic joint.Haemophilia1998https://conductscience.org/library/papers/9873783PubMed
1312828668The pharmacokinetics of clotting factor therapy.Haemophilia2003https://conductscience.org/library/papers/12828668PubMed
1427214717Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A.Haemophilia1997https://conductscience.org/library/papers/27214717PubMed
15327532Hemophilia A prophylaxis with factor VIII concentrate in a home-treatment program: a controlled study.Scand J Haematol Suppl1977https://conductscience.org/library/papers/327532PubMed
1611260054Long-term outcome of individualized prophylactic treatment of children with severe haemophilia.Br J Haematol2001https://conductscience.org/library/papers/11260054PubMed
1711895765The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia.Blood2002https://conductscience.org/library/papers/11895765PubMed
181640190Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.J Intern Med1992https://conductscience.org/library/papers/1640190PubMed
1912410643Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.Haemophilia2002https://conductscience.org/library/papers/12410643PubMed
207408294A radiologic classification of hemophilic arthropathy.Clin Orthop Relat Res1980https://conductscience.org/library/papers/7408294PubMed

See all 28 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
F82157PubTator's text mininghttps://conductscience.org/library/genes/2157

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/23908669

GET https://conductscience.org/api/papers/v1/23908669/references?page=2